Anthony P. Zook - Apr 1, 2025 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Role
Chief Executive Officer, Director
Signature
/s/ Ali Olivo, Attorney-in-Fact
Stock symbol
NEO
Transactions as of
Apr 1, 2025
Transactions value $
$0
Form type
4
Date filed
4/3/2025, 04:06 PM
Previous filing
Feb 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NEO Common Stock 11.3K Apr 1, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEO Stock Option (Right to Buy) Award $0 +730K $0.00 730K Apr 1, 2025 Common Stock 730K $10.44 Direct F1, F2
transaction NEO Restricted Stock Unit Award $0 +421K $0.00 421K Apr 1, 2025 Common Stock 421K $0.00 Direct F3, F4
holding NEO Stock Option (Right to Buy) 8.35K Apr 1, 2025 Common Stock 8.35K $14.82 Direct
holding NEO Stock Option (Right to Buy) 8.67K Apr 1, 2025 Common Stock 8.67K $13.71 Direct
holding NEO Restricted Stock Unit 12.3K Apr 1, 2025 Common Stock 12.3K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
F2 On April 1, 2025, Mr. Zook was granted 729,927 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F3 On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F4 Once vested, the shares of common stock are not subject to expiration.